

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- An opportunity for Trump: Position U.S. cancer science to lead the world
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - In The Headlines: Wafik El-Deiry on how “America First” means investing in NCI
- Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges